Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 185

1.

Recombinant Haemagglutinin Derived From the Ciliated Protozoan Tetrahymena thermophila Is Protective Against Influenza Infection.

Jawinski K, Hartmann M, Singh C, Kinnear E, Busse DC, Ciabattini A, Fiorino F, Medaglini D, Trombetta CM, Montomoli E, Contreras V, Le Grand R, Coiffier C, Primard C, Verrier B, Tregoning JS.

Front Immunol. 2019 Nov 13;10:2661. doi: 10.3389/fimmu.2019.02661. eCollection 2019.

2.

Tailoring mRNA Vaccine to Balance Innate/Adaptive Immune Response.

Linares-Fernández S, Lacroix C, Exposito JY, Verrier B.

Trends Mol Med. 2019 Nov 4. pii: S1471-4914(19)30244-8. doi: 10.1016/j.molmed.2019.10.002. [Epub ahead of print] Review.

PMID:
31699497
3.

Synthetic self-assembling ADDomer platform for highly efficient vaccination by genetically encoded multiepitope display.

Vragniau C, Bufton JC, Garzoni F, Stermann E, Rabi F, Terrat C, Guidetti M, Josserand V, Williams M, Woods CJ, Viedma G, Bates P, Verrier B, Chaperot L, Schaffitzel C, Berger I, Fender P.

Sci Adv. 2019 Sep 25;5(9):eaaw2853. doi: 10.1126/sciadv.aaw2853. eCollection 2019 Sep.

4.

Molecular modelling of TLR agonist Pam3CSK4 entrapment in PLA nanoparticles as a tool to explain loading efficiency and functionality.

Lamrayah M, Charriaud F, Hu S, Megy S, Terreux R, Verrier B.

Int J Pharm. 2019 Sep 10;568:118569. doi: 10.1016/j.ijpharm.2019.118569. Epub 2019 Jul 26.

PMID:
31352045
5.

AS1411-conjugated gold nanoparticles affect cell proliferation through a mechanism that seems independent of nucleolin.

Kabirian-Dehkordi S, Chalabi-Dchar M, Mertani HC, Le Guellec D, Verrier B, Diaz JJ, Mehrgardi MA, Bouvet P.

Nanomedicine. 2019 Oct;21:102060. doi: 10.1016/j.nano.2019.102060. Epub 2019 Jul 20.

PMID:
31336175
6.

Self-assembled amphiphilic copolymers as dual delivery system for immunotherapy.

Trimaille T, Lacroix C, Verrier B.

Eur J Pharm Biopharm. 2019 Sep;142:232-239. doi: 10.1016/j.ejpb.2019.06.022. Epub 2019 Jun 20. Review.

PMID:
31229673
7.

The STING ligand cGAMP potentiates the efficacy of vaccine-induced CD8+ T cells.

Gutjahr A, Papagno L, Nicoli F, Kanuma T, Kuse N, Cabral-Piccin MP, Rochereau N, Gostick E, Lioux T, Perouzel E, Price DA, Takiguchi M, Verrier B, Yamamoto T, Paul S, Appay V.

JCI Insight. 2019 Apr 4;4(7). pii: 125107. doi: 10.1172/jci.insight.125107. eCollection 2019 Apr 4.

8.

A high mucosal blocking score is associated with HIV protection.

Girard A, Rallón N, Benito JM, Jospin F, Rodriguez C, Chanut B, Benjelloun F, Del Romero J, Verrier B, Lucht F, Pin JJ, Genin C, Biasin M, Clerici M, Paul S.

AIDS. 2019 Mar 1;33(3):411-423. doi: 10.1097/QAD.0000000000002099.

PMID:
30703069
9.

Poly(lactic acid) nanoparticles and cell-penetrating peptide potentiate mRNA-based vaccine expression in dendritic cells triggering their activation.

Coolen AL, Lacroix C, Mercier-Gouy P, Delaune E, Monge C, Exposito JY, Verrier B.

Biomaterials. 2019 Mar;195:23-37. doi: 10.1016/j.biomaterials.2018.12.019. Epub 2018 Dec 21.

PMID:
30610991
10.

Nanoparticle-Based Dressing: The Future of Wound Treatment?: (Trends in Biotechnology 35, 770-784, 2017).

Berthet M, Gauthier Y, Lacroix C, Verrier B, Monge C.

Trends Biotechnol. 2018 Jan;36(1):119. doi: 10.1016/j.tibtech.2017.08.007. Epub 2017 Sep 22. No abstract available.

PMID:
28947211
11.

Antibiotic incorporation in jet-sprayed nanofibrillar biodegradable scaffolds for wound healing.

Dzikowski M, Castanié N, Guedon A, Verrier B, Primard C, Sohier J.

Int J Pharm. 2017 Nov 5;532(2):802-812. doi: 10.1016/j.ijpharm.2017.08.117. Epub 2017 Aug 31.

PMID:
28864389
12.

Comparison of four different fuller's earth formulations in skin decontamination.

Roul A, Le CA, Gustin MP, Clavaud E, Verrier B, Pirot F, Falson F.

J Appl Toxicol. 2017 Dec;37(12):1527-1536. doi: 10.1002/jat.3506. Epub 2017 Jul 26.

PMID:
28745436
13.

Exploiting Natural Cross-reactivity between Human Immunodeficiency Virus (HIV)-1 p17 Protein and Anti-gp41 2F5 Antibody to Induce HIV-1 Neutralizing Responses In Vivo.

Verrier B, Paul S, Terrat C, Bastide L, Ensinas A, Phelip C, Chanut B, Bulens-Grassigny L, Jospin F, Guillon C.

Front Immunol. 2017 Jun 30;8:770. doi: 10.3389/fimmu.2017.00770. eCollection 2017.

14.

Improving bioassay sensitivity through immobilization of bio-probes onto reactive micelles.

Jiménez-Sánchez G, Terrat C, Verrier B, Gigmes D, Trimaille T.

Chem Commun (Camb). 2017 Jul 13;53(57):8062-8065. doi: 10.1039/c7cc02057k.

PMID:
28674711
15.

Nanoparticle-Based Dressing: The Future of Wound Treatment?

Berthet M, Gauthier Y, Lacroix C, Verrier B, Monge C.

Trends Biotechnol. 2017 Aug;35(8):770-784. doi: 10.1016/j.tibtech.2017.05.005. Epub 2017 Jun 20. Review. Erratum in: Trends Biotechnol. 2018 Jan;36(1):119.

PMID:
28645529
16.

Ternary polysaccharide complexes: Colloidal drug delivery systems stabilized in physiological media.

Wu D, Ensinas A, Verrier B, Cuvillier A, Champier G, Paul S, Delair T.

Carbohydr Polym. 2017 Sep 15;172:265-274. doi: 10.1016/j.carbpol.2017.05.051. Epub 2017 May 21.

PMID:
28606534
17.

Critical Role for Skin-Derived Migratory DCs and Langerhans Cells in TFH and GC Responses after Intradermal Immunization.

Levin C, Bonduelle O, Nuttens C, Primard C, Verrier B, Boissonnas A, Combadière B.

J Invest Dermatol. 2017 Sep;137(9):1905-1913. doi: 10.1016/j.jid.2017.04.016. Epub 2017 Apr 28.

18.

Cutting Edge: A Dual TLR2 and TLR7 Ligand Induces Highly Potent Humoral and Cell-Mediated Immune Responses.

Gutjahr A, Papagno L, Nicoli F, Lamoureux A, Vernejoul F, Lioux T, Gostick E, Price DA, Tiraby G, Perouzel E, Appay V, Verrier B, Paul S.

J Immunol. 2017 Jun 1;198(11):4205-4209. doi: 10.4049/jimmunol.1602131. Epub 2017 Apr 21.

19.

Specific and Efficient Uptake of Surfactant-Free Poly(Lactic Acid) Nanovaccine Vehicles by Mucosal Dendritic Cells in Adult Zebrafish after Bath Immersion.

Rességuier J, Delaune E, Coolen AL, Levraud JP, Boudinot P, Le Guellec D, Verrier B.

Front Immunol. 2017 Feb 27;8:190. doi: 10.3389/fimmu.2017.00190. eCollection 2017.

20.

Neutralizing and Targeting Properties of a New Set of α4β7-Specific Antibodies Are Influenced by Their Isotype.

Girard A, Jelicic K, Van Ryk D, Rochereau N, Cicala C, Arthos J, Noailly B, Genin C, Verrier B, Laurant S, Razanajaoana-Doll D, Pin JJ, Paul S.

J Acquir Immune Defic Syndr. 2017 May 1;75(1):118-127. doi: 10.1097/QAI.0000000000001307.

PMID:
28177967
21.

Tuning the Hydrophilic/Hydrophobic Balance to Control the Structure of Chitosan Films and Their Protein Release Behavior.

Becerra J, Sudre G, Royaud I, Montserret R, Verrier B, Rochas C, Delair T, David L.

AAPS PharmSciTech. 2017 May;18(4):1070-1083. doi: 10.1208/s12249-016-0678-9. Epub 2016 Dec 14.

PMID:
27975192
22.

Poly(Lactic Acid) Nanoparticles Targeting α5β1 Integrin as Vaccine Delivery Vehicle, a Prospective Study.

Dalzon B, Lebas C, Jimenez G, Gutjahr A, Terrat C, Exposito JY, Verrier B, Lethias C.

PLoS One. 2016 Dec 14;11(12):e0167663. doi: 10.1371/journal.pone.0167663. eCollection 2016.

23.

Biodegradable Polymeric Nanoparticles-Based Vaccine Adjuvants for Lymph Nodes Targeting.

Gutjahr A, Phelip C, Coolen AL, Monge C, Boisgard AS, Paul S, Verrier B.

Vaccines (Basel). 2016 Oct 12;4(4). pii: E34. Review.

24.

Innovative drug vehicle for local treatment of inflammatory skin diseases: Ex vivo and in vivo screening of five topical formulations containing poly(lactic acid) (PLA) nanoparticles.

Boisgard AS, Lamrayah M, Dzikowski M, Salmon D, Kirilov P, Primard C, Pirot F, Fromy B, Verrier B.

Eur J Pharm Biopharm. 2017 Jul;116:51-60. doi: 10.1016/j.ejpb.2016.09.021. Epub 2016 Oct 1.

PMID:
27702687
25.

Triggering Intracellular Receptors for Vaccine Adjuvantation.

Gutjahr A, Tiraby G, Perouzel E, Verrier B, Paul S.

Trends Immunol. 2016 Oct;37(10):716. doi: 10.1016/j.it.2016.08.005. Epub 2016 Aug 30. No abstract available.

PMID:
27595229
26.

First Membrane Proximal External Region-Specific Anti-HIV1 Broadly Neutralizing Monoclonal IgA1 Presenting Short CDRH3 and Low Somatic Mutations.

Benjelloun F, Oruc Z, Thielens N, Verrier B, Champier G, Vincent N, Rochereau N, Girard A, Jospin F, Chanut B, Genin C, Cogné M, Paul S.

J Immunol. 2016 Sep 1;197(5):1979-88. doi: 10.4049/jimmunol.1600309. Epub 2016 Aug 1.

27.

Triggering Intracellular Receptors for Vaccine Adjuvantation.

Gutjahr A, Tiraby G, Perouzel E, Verrier B, Paul S.

Trends Immunol. 2016 Sep;37(9):573-587. doi: 10.1016/j.it.2016.07.001. Epub 2016 Jul 27. Review. Erratum in: Trends Immunol. 2016 Oct;37(10 ):716.

PMID:
27474233
28.

Zinc-Stabilized Chitosan-Chondroitin Sulfate Nanocomplexes for HIV-1 Infection Inhibition Application.

Wu D, Ensinas A, Verrier B, Primard C, Cuvillier A, Champier G, Paul S, Delair T.

Mol Pharm. 2016 Sep 6;13(9):3279-91. doi: 10.1021/acs.molpharmaceut.6b00568. Epub 2016 Aug 8.

PMID:
27454202
29.

Evaluation of polylactic acid nanoparticles safety using Drosophila model.

Legaz S, Exposito JY, Lethias C, Viginier B, Terzian C, Verrier B.

Nanotoxicology. 2016 Oct;10(8):1136-43. doi: 10.1080/17435390.2016.1181806. Epub 2016 May 16. Erratum in: Nanotoxicology. 2016 Oct;10(8):i.

PMID:
27108761
30.

Drug loaded composite oxidized pectin and gelatin networks for accelerated wound healing.

Tummalapalli M, Berthet M, Verrier B, Deopura BL, Alam MS, Gupta B.

Int J Pharm. 2016 May 30;505(1-2):234-45. doi: 10.1016/j.ijpharm.2016.04.007. Epub 2016 Apr 5.

PMID:
27063849
31.

Controlled association and delivery of nanoparticles from jet-sprayed hybrid microfibrillar matrices.

Keloglu N, Verrier B, Trimaille T, Sohier J.

Colloids Surf B Biointerfaces. 2016 Apr 1;140:142-149. doi: 10.1016/j.colsurfb.2015.12.039. Epub 2015 Dec 28.

PMID:
26752211
32.

Directing vaccine immune responses to mucosa by nanosized particulate carriers encapsulating NOD ligands.

Pavot V, Climent N, Rochereau N, Garcia F, Genin C, Tiraby G, Vernejoul F, Perouzel E, Lioux T, Verrier B, Paul S.

Biomaterials. 2016 Jan;75:327-339. doi: 10.1016/j.biomaterials.2015.10.034. Epub 2015 Nov 3.

PMID:
26539801
33.

Composite wound dressings of pectin and gelatin with aloe vera and curcumin as bioactive agents.

Tummalapalli M, Berthet M, Verrier B, Deopura BL, Alam MS, Gupta B.

Int J Biol Macromol. 2016 Jan;82:104-13. doi: 10.1016/j.ijbiomac.2015.10.087. Epub 2015 Nov 1.

PMID:
26529192
34.

Micelle-Based Adjuvants for Subunit Vaccine Delivery.

Trimaille T, Verrier B.

Vaccines (Basel). 2015 Sep 25;3(4):803-13. doi: 10.3390/vaccines3040803. Review.

35.

Delivery of antigen to nasal-associated lymphoid tissue microfold cells through secretory IgA targeting local dendritic cells confers protective immunity.

Rochereau N, Pavot V, Verrier B, Jospin F, Ensinas A, Genin C, Corthésy B, Paul S.

J Allergy Clin Immunol. 2016 Jan;137(1):214-222.e2. doi: 10.1016/j.jaci.2015.07.042. Epub 2015 Sep 26.

PMID:
26414879
36.

New easy handling and sampling device for bioavailability screening of topical formulations.

Salmon D, Gilbert E, Gioia B, Haftek M, Pivot C, Verrier B, Pirot F.

Eur J Dermatol. 2015 Apr;25 Suppl 1:23-9. doi: 10.1684/ejd.2015.2551.

PMID:
26083671
37.

A Novel Alpha Cardiac Actin (ACTC1) Mutation Mapping to a Domain in Close Contact with Myosin Heavy Chain Leads to a Variety of Congenital Heart Defects, Arrhythmia and Possibly Midline Defects.

Augière C, Mégy S, El Malti R, Boland A, El Zein L, Verrier B, Mégarbané A, Deleuze JF, Bouvagnet P.

PLoS One. 2015 Jun 10;10(6):e0127903. doi: 10.1371/journal.pone.0127903. eCollection 2015.

38.

A purified truncated form of yeast Gal4 expressed in Escherichia coli and used to functionalize poly(lactic acid) nanoparticle surface is transcriptionally active in cellulo.

Legaz S, Exposito JY, Borel A, Candusso MP, Megy S, Montserret R, Lahaye V, Terzian C, Verrier B.

Protein Expr Purif. 2015 Sep;113:94-101. doi: 10.1016/j.pep.2015.05.009. Epub 2015 May 19.

PMID:
26002116
39.

Poly(lactic acid) and poly(lactic-co-glycolic acid) particles as versatile carrier platforms for vaccine delivery.

Pavot V, Berthet M, Rességuier J, Legaz S, Handké N, Gilbert SC, Paul S, Verrier B.

Nanomedicine (Lond). 2014 Dec;9(17):2703-18. doi: 10.2217/nnm.14.156.

PMID:
25529572
40.

Secretory IgA as a vaccine carrier for delivery of HIV antigen to M cells.

Rochereau N, Pavot V, Verrier B, Ensinas A, Genin C, Corthésy B, Paul S.

Eur J Immunol. 2015 Mar;45(3):773-9. doi: 10.1002/eji.201444816. Epub 2015 Jan 14.

41.

Cutting edge: New chimeric NOD2/TLR2 adjuvant drastically increases vaccine immunogenicity.

Pavot V, Rochereau N, Rességuier J, Gutjahr A, Genin C, Tiraby G, Perouzel E, Lioux T, Vernejoul F, Verrier B, Paul S.

J Immunol. 2014 Dec 15;193(12):5781-5. doi: 10.4049/jimmunol.1402184. Epub 2014 Nov 12.

42.

Preparation and in vitro evaluation of imiquimod loaded polylactide-based micelles as potential vaccine adjuvants.

Jiménez-Sánchez G, Pavot V, Chane-Haong C, Handké N, Terrat C, Gigmes D, Trimaille T, Verrier B.

Pharm Res. 2015 Jan;32(1):311-20. doi: 10.1007/s11095-014-1465-5. Epub 2014 Sep 24.

PMID:
25248333
43.

Loading dendritic cells with PLA-p24 nanoparticles or MVA expressing HIV genes induces HIV-1-specific T cell responses.

Climent N, Munier S, Piqué N, García F, Pavot V, Primard C, Casanova V, Gatell JM, Verrier B, Gallart T.

Vaccine. 2014 Oct 29;32(47):6266-76. doi: 10.1016/j.vaccine.2014.09.010. Epub 2014 Sep 19.

PMID:
25240755
44.

Recent progress in HIV vaccines inducing mucosal immune responses.

Pavot V, Rochereau N, Lawrence P, Girard MP, Genin C, Verrier B, Paul S.

AIDS. 2014 Jul 31;28(12):1701-18. doi: 10.1097/QAD.0000000000000308. Review.

PMID:
25009956
45.

Large-scale nucleotide optimization of simian immunodeficiency virus reduces its capacity to stimulate type I interferon in vitro.

Vabret N, Bailly-Bechet M, Lepelley A, Najburg V, Schwartz O, Verrier B, Tangy F.

J Virol. 2014 Apr;88(8):4161-72. doi: 10.1128/JVI.03223-13. Epub 2014 Jan 29.

46.

Particle-based transcutaneous administration of HIV-1 p24 protein to human skin explants and targeting of epidermal antigen presenting cells.

Rancan F, Amselgruber S, Hadam S, Munier S, Pavot V, Verrier B, Hackbarth S, Combadiere B, Blume-Peytavi U, Vogt A.

J Control Release. 2014 Feb 28;176:115-22. doi: 10.1016/j.jconrel.2013.12.022. Epub 2013 Dec 31.

PMID:
24384300
47.

Dectin-1 is essential for reverse transcytosis of glycosylated SIgA-antigen complexes by intestinal M cells.

Rochereau N, Drocourt D, Perouzel E, Pavot V, Redelinghuys P, Brown GD, Tiraby G, Roblin X, Verrier B, Genin C, Corthésy B, Paul S.

PLoS Biol. 2013 Sep;11(9):e1001658. doi: 10.1371/journal.pbio.1001658. Epub 2013 Sep 17.

48.

Elaboration of glycopolymer-functionalized micelles from an N-vinylpyrrolidone/lactide-based reactive copolymer platform.

Handké N, Lahaye V, Bertin D, Delair T, Verrier B, Gigmes D, Trimaille T.

Macromol Biosci. 2013 Sep;13(9):1213-20. doi: 10.1002/mabi.201300102. Epub 2013 Jul 4.

PMID:
23825039
49.

Generation of HIV-1 potent and broad neutralizing antibodies by immunization with postfusion HR1/HR2 complex.

Dawood R, Benjelloun F, Pin JJ, Kone A, Chanut B, Jospin F, Lucht F, Verrier B, Moog C, Genin C, Paul S.

AIDS. 2013 Mar 13;27(5):717-30. doi: 10.1097/QAD.0b013e32835cfca5.

PMID:
23719346
50.

Secretory IgA specific for MPER can protect from HIV-1 infection in vitro.

Benjelloun F, Dawood R, Urcuqui-Inchima S, Rochereau N, Chanut B, Verrier B, Lucht F, Genin C, Paul S.

AIDS. 2013 Jul 31;27(12):1992-5.

PMID:
23696073

Supplemental Content

Loading ...
Support Center